Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-243 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Maximum observed serum concentration (Cmax) of ABBV-243
Area under the serum concentration-time curve (AUC) from time 0 to the time of last measurable concentration (AUCt) of ABBV-243
AUC from time 0 to infinite time (AUCinf) of ABBV-243
Terminal phase elimination rate constant of ABBV-243
Terminal phase elimination half-life of ABBV-243
Confirmed Positive ADA Results.
| Arm | Type | Description |
|---|---|---|
| Group 1: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 2: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 3: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 4: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1 |
| Group 5: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single subcutaneous (SC) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 6: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single subcutaneous (SC) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 7: ABBV-243 or Placebo | EXPERIMENTAL | Han Chinese participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1 |
| Group 8: ABBV-243 or Placebo | EXPERIMENTAL | Japanese participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1 |
| Name | Type | Description |
|---|---|---|
| ABBV-243 | DRUG | Intravenous (IV) Infusion |
| Placebo | DRUG | Intravenous (IV) Infusion |
Inclusion Criteria: * Individuals between 18 and 60 years of age inclusive at the time of Screening. * BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * Females, Non-Childbearing ...
ABBV-243 is an investigational small molecule being studied in healthy volunteers. It is currently in a Phase 1 clinical trial to evaluate its safety and pharmacokinetics. The drug is not approved for any condition and is in early-stage clinical development.
ABBV-243 is being developed by AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting a Phase 1 study of the drug in healthy adults in the United States.
ABBV-243 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety and pharmacokinetics in healthy adults.
ABBV-243 is being studied in a single Phase 1 clinical trial with the identifier NCT07306754. This randomized, double-blind, controlled study is evaluating the safety and pharmacokinetics of ABBV-243 in healthy adults. The trial is recruiting 66 participants in the United States.
Yes, ABBV-243 is a small molecule drug. It is being developed as an oral or injectable therapeutic, though the specific route of administration is not specified. The drug is in Phase 1 testing to evaluate its safety and how the body processes it.